TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation and Validation of a New Questionnaire to Identify and Quantify Abdominal Symptoms in Patients With Cystic Fibrosis Following FDA Guidelines: the CF Abd-Score (Primarily Named JenAbdomen-CF Score)
Brief Summary: Development, validation and evaluation of a new multimodal questionnaire to assess and quantify the abdominal involvement in patients with the inherited life shortening multi-organ disease Cystic fibrosis.

In the stepwhise development of the patient reported outcome measures (PROM) repeadedly, CF-patients, their families as well as professionals working in different fields of CF-care will be included.


Options:
A: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
D: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Quality of Life in Hematologic Cancer Survivors by Closing the Exercise Intention-Behavior Gap: a Phase II Randomized Controlled Trial of a Theory-based, Telephone-delivered Exercise Counselling Intervention
Brief Summary: This study evaluates the impact of a 12-week theory-based exercise telephone counselling program (versus a self-directed exercise group) on closing the exercise intention-behavior gap in a sample of hematologic cancer survivors.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Exercise
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
C: Arm Label: Facebook-based Self-help Comparison; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facebook-based Self-help Comparison | Arm Label: Facebook-based Messages/Website; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook-based Messages/Website | Intervention Type: BEHAVIORAL; Name: Facebook-based Messages/Website; Assigned to Arm(s): Facebook-based Messages/Website | Intervention Type: BEHAVIORAL; Name: Facebook-based Self-help Comparison; Assigned to Arm(s): Facebook-based Self-help Comparison
D: Arm Label: Telephone Counselling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counselling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telephone counselling; Assigned to Arm(s): Telephone Counselling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Two-arm, Interventional, Prospective, Open-label, Multi-center Trial to Evaluate the Safety & Effectiveness of FMT for Treatment of Adult Patients With Primary or Recurrent CDI, Using a Novel, Standardized Microbiota Transplantation System
Brief Summary: This study is a two-arm, interventional, prospective, open-label, multi-center clinical trial with randomized and non-randomized study groups to evaluate the safety and effectiveness of faecal microbiota transplantation (FMT) for the treatment of adult patients suffering from primary or recurrent Clostridium difficile infection (CDI), using a novel, standardized microbiota transplantation system.


Options:
A: Arm Label: Fecal Transplant; Type: EXPERIMENTAL; Interventions: Biological: Fecal Transplant | Arm Label: Oral Vancomycin Taper; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Oral Vancomycin Taper | Intervention Type: BIOLOGICAL; Name: Fecal Transplant; Assigned to Arm(s): Fecal Transplant
B: Arm Label: Fecal transplantation; Type: EXPERIMENTAL; Interventions: Biological: Fecal transplantation | Arm Label: Placebo fecal transplantation; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo fecal transplant | Intervention Type: BIOLOGICAL; Name: Fecal transplantation; Assigned to Arm(s): Fecal transplantation | Intervention Type: OTHER; Name: Placebo fecal transplant; Assigned to Arm(s): Placebo fecal transplantation
C: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT
D: Arm Label: Recurrent CDI FMT; Type: EXPERIMENTAL; Interventions: Biological: faecal human microbiota transplant (FMT) | Arm Label: Primary CDI antibiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin or Fidaxomicin | Arm Label: Primary CDI FMT; Type: EXPERIMENTAL; Interventions: Biological: faecal human microbiota transplant (FMT) | Intervention Type: BIOLOGICAL; Name: faecal human microbiota transplant (FMT); Assigned to Arm(s): Primary CDI FMT, Recurrent CDI FMT | Intervention Type: DRUG; Name: Vancomycin or Fidaxomicin; Assigned to Arm(s): Primary CDI antibiotic

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Brief Summary: This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of orally administered vadadustat in Japanese participants with anemia secondary to Non-dialysis Dependent Chronic Kidney Disease (NDD-CKD).


Options:
A: Arm Label: Vadadustat, Dose 1; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat, Dose 2; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat, Dose 3; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat, Dose 1, Vadadustat, Dose 2, Vadadustat, Dose 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: MT-6548; Type: EXPERIMENTAL; Interventions: Drug: MT-6548 | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: MT-6548; Assigned to Arm(s): MT-6548 | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Molidustat, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 160 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat, 120 mg, Molidustat, 160 mg, Molidustat, 40 mg, Molidustat, 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Molidustat, 120 mg, Molidustat, 160 mg, Molidustat, 40 mg, Molidustat, 80 mg
D: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Brief Summary: This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of orally administered vadadustat in Japanese participants with anemia secondary to Dialysis-dependent Chronic Kidney Disease (DD-CKD).


Options:
A: Arm Label: 0.5mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 2mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 5mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Other: Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): 0.5mg GSK1278863, 2mg GSK1278863, 5mg GSK1278863 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Alfa | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat
C: Arm Label: Vadadustat, Dose 1; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat, Dose 2; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat, Dose 3; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat, Dose 1, Vadadustat, Dose 2, Vadadustat, Dose 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BAY85-3934 (25mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: BAY85-3934 (50mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: BAY85-3934 (75mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Biological: Darbepoetin alfa | Intervention Type: DRUG; Name: BAY85-3934; Assigned to Arm(s): BAY85-3934 (25mg), BAY85-3934 (50mg), BAY85-3934 (75mg) | Intervention Type: BIOLOGICAL; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized Study of Long-term Hemodialysis Catheter Removal, Versus Guidewire Exchange to Treat Catheter Related Blood Stream Infection
Brief Summary: Prospective, randomized Study of tunneled cuffed hemodialysis catheter removal and delayed replacement, versus exchange over a guidewire to treat catheter related blood stream infection


Options:
A: Arm Label: group A; Type: ACTIVE_COMPARATOR; Interventions: Device: catheter replacement | Arm Label: group B; Type: ACTIVE_COMPARATOR; Interventions: Device: catheter replacement | Intervention Type: DEVICE; Name: catheter replacement; Assigned to Arm(s): group A, group B
B: Arm Label: Antibiotic Lock Solution; Type: EXPERIMENTAL; Interventions: Drug: tigecycline, N-acetylcysteine, heparin combination | Arm Label: Guide-wire Exchange; Type: ACTIVE_COMPARATOR; Interventions: Device: guide-wire exchange | Intervention Type: DRUG; Name: tigecycline, N-acetylcysteine, heparin combination; Assigned to Arm(s): Antibiotic Lock Solution | Intervention Type: DEVICE; Name: guide-wire exchange; Assigned to Arm(s): Guide-wire Exchange
C: Arm Label: ethanol; Type: EXPERIMENTAL; Interventions: Other: Ethanol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Ethanol | Intervention Type: OTHER; Name: Ethanol; Assigned to Arm(s): ethanol, placebo
D: Arm Label: ClearGuard HD end cap; Type: ACTIVE_COMPARATOR; Interventions: Device: ClearGuard HD end cap | Arm Label: Standard hemodialysis end cap; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ClearGuard HD end cap; Assigned to Arm(s): ClearGuard HD end cap

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study Of Doxorubicin Hydrochloride Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Sun Pharma Advanced Research Company Limited, India, And Caelyx® (Doxorubicin Hydrochloride) Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Schering-Plough, Belgium, in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer, Under Fed (Normal Breakfast) Conditions.
Brief Summary: This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.


Options:
A: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C
C: Arm Label: Pembrolizumab + paclitaxel ± bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Docetaxel | Arm Label: Placebo + paclitaxel ± bevacizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Other: Placebo for pembrolizumab, Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab | Intervention Type: OTHER; Name: Placebo for pembrolizumab; Assigned to Arm(s): Placebo + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab
D: Arm Label: SPARC-08-038; Type: EXPERIMENTAL; Interventions: Drug: SPARC-08-038, Drug: Ref-08-038 | Arm Label: Ref-08-038; Type: ACTIVE_COMPARATOR; Interventions: Drug: SPARC-08-038, Drug: Ref-08-038 | Intervention Type: DRUG; Name: SPARC-08-038; Assigned to Arm(s): Ref-08-038, SPARC-08-038 | Intervention Type: DRUG; Name: Ref-08-038; Assigned to Arm(s): Ref-08-038, SPARC-08-038

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Applying Wolbachia to Eliminate Dengue (AWED): A Non-blinded Cluster Randomised Controlled Trial to Assess the Efficacy of Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia
Brief Summary: This cluster randomised trial will evaluate the efficacy of Wolbachia-infected Aedes aegytpi mosquitoes in reducing dengue cases in Yogyakarta City, Indonesia


Options:
A: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Biological: Wolbachia-infected Aedes aegypti mosquitoes, Other: standard practice dengue control | Arm Label: Comparison arm; Type: OTHER; Interventions: Other: standard practice dengue control | Intervention Type: BIOLOGICAL; Name: Wolbachia-infected Aedes aegypti mosquitoes; Assigned to Arm(s): Intervention arm | Intervention Type: OTHER; Name: standard practice dengue control; Assigned to Arm(s): Comparison arm, Intervention arm
B: Arm Label: CYD Dengue Vaccine Group; Type: N/A; Interventions: N/A | Arm Label: Control Group; Type: N/A; Interventions: N/A
C: Arm Label: Dengue Vaccine Group; Type: EXPERIMENTAL; Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: Sodium chloride (NaCl) 0.9% | Intervention Type: BIOLOGICAL; Name: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Assigned to Arm(s): Dengue Vaccine Group | Intervention Type: BIOLOGICAL; Name: Placebo: Sodium chloride (NaCl) 0.9%; Assigned to Arm(s): Control Group
D: Arm Label: CYD Dengue Vaccine Group; Type: EXPERIMENTAL; Interventions: Biological: CYD Dengue Vaccine | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Inactivated rabies virus vaccine, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: CYD Dengue Vaccine; Assigned to Arm(s): CYD Dengue Vaccine Group | Intervention Type: BIOLOGICAL; Name: Inactivated rabies virus vaccine; Assigned to Arm(s): Control Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Brief Summary: The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who were clinically stable after having been treated with eculizumab for at least 6 months.


Options:
A: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ravulizumab, Biological: Eculizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Eculizumab, Ravulizumab | Intervention Type: BIOLOGICAL; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: OMS721; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721
C: Arm Label: OMS721 low dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Arm Label: OMS721 medium dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Arm Label: OMS721 high dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721 high dose, OMS721 low dose, OMS721 medium dose
D: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ravulizumab, Biological: Eculizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Eculizumab, Ravulizumab | Intervention Type: BIOLOGICAL; Name: Eculizumab; Assigned to Arm(s): Eculizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Brief Summary: This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition. The purpose of the study is to find out whether a medicine called empagliflozin lowers the chances of patients having to go to hospital for heart failure and whether it improves their survival. The study is open to patients with a type of chronic heart failure called chronic heart failure with preserved ejection fraction.

Participants stay in the study until researchers have enough information about how effective empagliflozin is. It is expected that participants who enter at the very beginning of the enrolment period may be in the study for over 3 years, while participants who enter near the end of the enrolment period may be in the study for less than 2 years. The participants are put into 2 groups. It is decided by chance who gets into which group. One group gets empagliflozin tablets every day and the other group gets placebo tablets every day. Placebo tablets look like empagliflozin tablets but contain no medicine.

Participants visit the doctors regularly. During these visits, the doctors collect information about the participant's health. The doctors want to know how many patients had to go to hospital because of heart failure or who died from cardiovascular disease.


Options:
A: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
B: Arm Label: CLOSE guided PVI and insertable cardiac monitor; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation; Assigned to Arm(s): CLOSE guided PVI and insertable cardiac monitor
C: Arm Label: Left Atrial Ablation; Type: ACTIVE_COMPARATOR; Interventions: Device: Left atrial ablation | Arm Label: Rate or Rhythm Control Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate or Rhythm Control Therapy | Intervention Type: DEVICE; Name: Left atrial ablation; Assigned to Arm(s): Left Atrial Ablation | Intervention Type: DRUG; Name: Rate or Rhythm Control Therapy; Assigned to Arm(s): Rate or Rhythm Control Therapy
D: Arm Label: 10 mg Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): 10 mg Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D